Results for icotrokinra (JNJ-2113) have shown the drug’s potential to offer significant relief for patients suffering from moderate-to-severe plaque psorias ...

Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...

Johnson & Johnson (NYSE: JNJ) has announced encouraging results from its Phase 3 investigational study of icotrokinra ...

Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

Johnson & Johnson (J&J) and Protagonist Therapeutics have announced positive top-line results from a late-stage study of ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the chronic skin condition.

The companies’ icotrokinra, or JNJ-2113, significantly cleared skin compared to placebo in patients with moderate to severe ...

The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at ...

IL-23 receptor antagonist icotrokinra hit co-primary phase III endpoints in moderate to severe plaque psoriasis, positioning the oral peptide at the forefront of a multibillion-dollar franchise for ...